LUMIBIRD

REVENUES FOR THE FIRST 9 MONTHS OF 2023: €139.0M (+11%) - Seite 2

After the strong growth in H1, the Lidar segment recorded a temporary decline in sales in the third quarter (-24% at €4.1m), although business remains buoyant, with growth of 11% to €18.3m over the first 9 months.

The Industrial and Scientific activities are stable in Q3 (+1% at €9.1m), with 9-month sales, down 8% at €23.9m, still affected by capacity restrictions at the start of the year.

The Medical division, meanwhile, posted sales of €21.8m in the 3rd quarter (+2% and +6% at constant exchange rates). Over 9-months, sales grew by 9% to €73.0m (up 12% at constant exchange rates). The division's sales are split between diagnostics (25%) and treatment (75%). This growth was driven by new product launches in several market segments and marketing authorisations in new geographical areas.

By Geography

The breakdown of 9 months sales by division and by geographical area is as follows:

Revenues (€m)	Photonics	Chg.	Medical	Chg.
EMEA	33.5	+29%	23.9	+20%
Americas	12.7	-1%	20.4	-5%
Asia-Pacific	15.0	+24%	18.6	+11%
ROW	4.7	-36%	10.1	+19%
Total	65.9	+13%	73.0	+9%

Unaudited data

Strong growth in the Photonics division in Europe (+29%) was driven by France and Sweden. Sales in the United States (-1%) catching up in the 3rd quarter for some of the delay caused by the postponement of deliveries to certain industrial customers in the 1st half of the year.

The Medical division's sales for the first 9 months of the year were similar to those recorded in H1, with strong growth in Europe (+20%) and the rest of the world (+19%, mainly Australia), good performances in Asia-Pacific, and sales in the United States which continue to be adversely affected by exchange rates and the delayed release of new products. Sales of these new products should have a favourable impact on business in the 4th quarter.